drugset / Trial / NCT05340634
Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.
Phase 4
Completed
90 enrolled
Margan Biotech
Grupo CINUSA (Centros de Investigación en Nutrición y Salud S.L.) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the efficacy of the combination of antioxidants ALA, NAC, Vit. B6 and SAMe as a dietary supplement, in the improvement of metabolic and endocrine parameters and clinical manifestations of PCOS.
Timeline
- Start
- 2020-04-20
- Primary completion
- 2022-02-02
- Completion
- 2022-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha lipoid acid | Other / unclassified | 75 mg | — |
| Subject | N-acetylcisteine | Other / unclassified | 100 mg | — |
| Subject | Pyridoxine | Unknown | 0.65 mg | — |
| Subject | S-adenosylmethionine | Other / unclassified | 200 mg | — |
| Subject | drospirenone | Unknown | 4 mg | Oral |